Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | IDE | P14735 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HLCS | P50747 | 6/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487045 | 0.89 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8509413 | 0.88 | TDP1 (0.57) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29495564 | 0.87 | TDP1 (0.55) | TDP1MEN1ABL1LMNAPKM | |
| Iodide SCHEMBL2533594 | 0.85 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL7006182 | 0.85 | TDP1 (0.54) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8958855 | 0.84 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL6838821 | 0.84 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL7258710 | 0.84 | TDP1 (0.56) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29884470 | 0.83 | TDP1 (0.64) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL425273 | 0.82 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119395003-A | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250027947-A1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-01-23 | — | — | US | claimed |
| CN-112424589-B | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3830556-B1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2024-11-13 | — | — | EP | claimed |
| US-12140596-B2 | Kits, microfluidics devices, and methods for performing biotin assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-11-12 | — | — | US | claimed |
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | claimed |
| CN-119395003-A | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250027947-A1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-112424589-B | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3830556-B1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2024-11-13 | — | — | EP | disclosed |
| US-12140596-B2 | Kits, microfluidics devices, and methods for performing biotin assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-8124364-B2 | Biotin derivatives | GLYCOREX TRANSPLANTATION AB (SE) | 2012-02-28 | — | — | US | disclosed |
| EP-1289563-B1 | METHOD FOR CONDITIONING AN AVIDIN OR STREPTAVIDIN COLUMN MATRIX IN AN EXTRACORPOREAL DEVICE | MITRA MEDICAL TECHNOLOGY AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| US-20040052784-A1 | Biotin derivatives | GLYCOREX TRANSPLANTATION AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1289563-A2 | BIOTIN DERIVATIVES | Mitra Medical Technology AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| US-20020159994-A1 | Biotin derivatives | GLYCOREX TRANSPLANTATION AB (SE) | 2002-10-31 | — | — | US | disclosed |
| WO-2001095857-A2 | REUSABLE EXTRACORPOREAL COLUMS LOADED WITH LIGAND-DIBIOTIN CONJUGATES | MITRA MEDICAL TECHNOLOGY AB (SE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052784-A1 | Biotin derivatives | BTD, HLCS, PROC | TDP1 4664/4885MEN1 1862/4885ABL1 3647/4885 |
| US-20020159994-A1 | Biotin derivatives | BTD, HLCS, PROC | TDP1 4662/4885MEN1 1631/4885ABL1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.